This study found that the serum IL‐6 and TNF‐α level of patients receiving olaparib maintenance treatment was lower than that of patients receiving conventional treatment, while the serum IFN‐γ level was increased, indicating olaparib maintenance treatment can significantly inhibit the inflammatory response of patients with ovarian cancer, which was in agreement with previous reports. The gene discussed is IL6; the disease is ovarian carcinoma.